Karunya K. Kandimalla is an associate professor of pharmaceutics at the University of Minnesota College of Pharmacy. After earning his PhD in pharmaceutics, he went on to conduct postdoctoral research work in the Department of Neurology at the Mayo Clinic College of Medicine in Rochester, Minnesota.
Following his postdoctoral work, Kandimalla served as an assistant professor in pharmaceutical sciences at the Florida A&M University, where he was awarded the 2010 Florida A&M University Emerging Researcher Award.
Kandimalla has authored numerous scholarly publications, and is a renowned expert in the general areas of biopharmaceutics and pharmacokinetics with emphasis on macromolecular transport and metabolism. The Kandimalla Laboratory has been developing experimental methods and models to facilitate the early diagnosis and treatment of Alzheimer’s disease. In collaboration with investigators at the Mayo Clinic, Kandimalla Lab has been investigating insulin signaling/trafficking deficiencies in the cerebral vasculature of Alzheimer’s disease patients and is discovering methods to reposition existing drugs to treat these patients. Further, Kandimalla Lab has been involved in designing nanotheranostics for the diagnosis and treatment of stroke and cerebral amyloid angiopathy in collaboration with the National High Magnetic Field Laboratory and the Mayo Clinic.
Kandimalla earned his Bachelor of Science in Pharmacy from Gulbarga University in India, and his Master of Science in Pharmaceutical Sciences from Florida A&M University in Tallahassee.